Calamos Advisors LLC - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6. A total of 36 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.5%.

Quarter-by-quarter ownership
Calamos Advisors LLC ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2021$4,535,000
+0.4%
5,000,0000.0%0.02%
-4.8%
Q2 2021$4,519,000
+9.3%
5,000,0000.0%0.02%
-8.7%
Q1 2021$4,136,000
+4.0%
5,000,0000.0%0.02%0.0%
Q4 2020$3,977,000
-1.5%
5,000,0000.0%0.02%
-11.5%
Q3 2020$4,037,000
+7.3%
5,000,0000.0%0.03%
-3.7%
Q2 2020$3,763,000
-7.6%
5,000,0000.0%0.03%
-15.6%
Q1 2020$4,072,000
-19.3%
5,000,0000.0%0.03%
+28.0%
Q4 2019$5,047,000
+17.3%
5,000,0000.0%0.02%
+8.7%
Q3 2019$4,301,000
-3.5%
5,000,0000.0%0.02%
-8.0%
Q2 2019$4,456,000
-10.2%
5,000,0000.0%0.02%
-19.4%
Q1 2019$4,960,000
+7.3%
5,000,0000.0%0.03%0.0%
Q4 2018$4,624,000
-8.3%
5,000,0000.0%0.03%
+10.7%
Q3 2018$5,044,000
+14.7%
5,000,0000.0%0.03%
+3.7%
Q2 2018$4,396,000
+8.9%
5,000,0000.0%0.03%
+3.8%
Q1 2018$4,038,000
+0.1%
5,000,0000.0%0.03%
+23.8%
Q4 2017$4,033,000
+3.4%
5,000,0000.0%0.02%
-30.0%
Q3 2017$3,900,000
-20.3%
5,000,0000.0%0.03%
-16.7%
Q2 2017$4,895,000
+5.0%
5,000,0000.0%0.04%
-2.7%
Q1 2017$4,660,000
+4.3%
5,000,0000.0%0.04%
+2.8%
Q4 2016$4,468,000
-20.3%
5,000,0000.0%0.04%
-10.0%
Q3 2016$5,603,0005,000,0000.04%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q2 2021
NameSharesValueWeighting ↓
SILVERBACK ASSET MANAGEMENT LLC 12,851,000$12,016,0002.95%
Context Capital Management, LLC 3,000,000$2,804,0002.24%
Man Investments (CH) AG 3,000,000$2,798,0001.76%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 42,500,000$39,540,0001.52%
MACKAY SHIELDS LLC 17,069,000$15,982,0000.73%
HIGHFIELDS CAPITAL MANAGEMENT LP 73,035,000$68,425,0000.63%
WOLVERINE ASSET MANAGEMENT LLC 42,307,000$39,554,0000.61%
LINDEN ADVISORS LP 14,122,000$13,194,0000.49%
GLG LLC 9,100,000$8,486,0000.47%
Jabre Capital Partners S.A. 3,400,000$3,179,0000.38%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders